

Kevin E Brown

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3146503/kevin-e-brown-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

1,993
citations

13
h-index

33
g-index

33
ext. papers

4,838
ext. citations

22.5
avg, IF

5.41
L-index

#	Paper	IF	Citations
23	Extended interval BNT162b2 vaccination enhances peak antibody generation.. <i>Npj Vaccines</i> , 2022 , 7, 14	9.5	24
22	Evaluation of disease severity during SARS-COV-2 reinfection, January 2020 to April 2021, England: an observational study.. <i>Journal of Infection</i> , 2022 ,	18.9	5
21	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	65
20	Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.. <i>Journal of Infection</i> , 2022 ,	18.9	4
19	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	224
18	VITT and Second Doses of Covid-19 Vaccine.. <i>New England Journal of Medicine</i> , 2021 ,	59.2	6
17	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. <i>Nature Communications</i> , 2021 , 12, 7217	17.4	17
16	Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e811-e819	9.5	11
15	Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. <i>Eurosurveillance</i> , 2021 , 26,	19.8	22
14	The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. <i>Eurosurveillance</i> , 2021 , 26,	19.8	1
13	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. <i>BMJ, The</i> , 2021 , 373, n1088	5.9	344
12	Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. <i>Journal of Infection</i> , 2021 , 82, 162-169	18.9	27
11	Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England. <i>Eurosurveillance</i> , 2021 , 26,	19.8	16
10	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021 , 385, 585-594	59.2	1058
9	mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. <i>ELife</i> , 2021 , 10,	8.9	9
8	Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e554-e560	9.5	13
7	Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England. <i>Journal of Infection</i> , 2021 , 83, 483-489	18.9	10

6	High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study, England. <i>EClinicalMedicine</i> , 2020 , 28, 100597	11.3	46
5	Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network. <i>Journal of Infection</i> , 2020 , 81, 785-792	18.9	23
4	Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers		7
3	Characterising post-COVID syndrome more than 6 months after acute infection in adults; prospective longitudinal cohort study, England		7
2	Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England		9
1	Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK		43